SynSysNet:integration of experimental data on synaptic protein-protein interactions with drug-target relations by von Eichborn, Joachim et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SynSysNet
Citation for published version:
von Eichborn, J, Dunkel, M, Gohlke, BO, Preissner, SC, Hoffmann, MF, Bauer, JMJ, Armstrong, D,
Schaefer, MH, Andrade-Navarro, MA, Le Novere, N, Croning, MDR, Grant, SGN, van Nierop, P, Smit, AB &
Preissner, R 2013, 'SynSysNet: integration of experimental data on synaptic protein-protein interactions with
drug-target relations' Nucleic Acids Research, vol 41, no. D1, pp. D834-D840. DOI: 10.1093/nar/gks1040
Digital Object Identifier (DOI):
10.1093/nar/gks1040
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Nucleic Acids Research
Publisher Rights Statement:
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by-nc/3.0/), which
permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is
properly cited. For commercial re-use, please contact
journals.permissions@oup.com.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
SynSysNet: integration of experimental data on
synaptic protein–protein interactions with
drug-target relations
Joachim von Eichborn1, Mathias Dunkel1, Bjo¨rn O. Gohlke1, Sarah C. Preissner1,
Michael F. Hoffmann1, Jakob M. J. Bauer1, J. D. Armstrong2, Martin H. Schaefer3,
Miguel A. Andrade-Navarro3, Nicolas Le Novere4, Michael D. R. Croning5,
Seth G. N. Grant5, Pim van Nierop6, August B. Smit6 and Robert Preissner1,*
1Structural Bioinformatics Group, Institute of Physiology, Charite´—University Medicine Berlin, Lindenberger Weg
80, 13125 Berlin, Germany, 2Institute for Neural Computation, School of Informatics, 10 Crichton Street,
Edinburgh, EH8 9AB, UK, 3Computational Biology Group, Max Delbru¨ck Center for Molecular Medicine,
Robert-Ro¨ssle-Strasse 10, 13125 Berlin, Germany, 4Babraham Institute, Babraham Research Campus,
Cambridge, CB22 3AT UK, 5Genes to Cognition Programme, Centre for Clinical Brain Sciences and Centre for
Neuroregeneration, The University of Edinburgh, Chancellors Building, 47 Little France Crescent, Edinburgh EH16
4SB, UK and 6Department of Molecular and Cellular Neurobiology, Center for Neurogenomics, Neuroscience
Campus Amsterdam, VU University Amsterdam, De Boelelaan 1085, 1081HV Amsterdam, The Netherlands
Received August 15, 2012; Revised September 29, 2012; Accepted October 6, 2012
ABSTRACT
We created SynSysNet, available online at http://
bioinformatics.charite.de/synsysnet, to provide a
platform that creates a comprehensive 4D network
of synaptic interactions. Neuronal synapses are fun-
damental structures linking nerve cells in the brain
and they are responsible for neuronal communica-
tion and information processing. These processes
are dynamically regulated by a network of
proteins. New developments in interaction prote-
omics and yeast two-hybrid methods allow
unbiased detection of interactors. The consolidation
of data from different resources and methods is
important to understand the relation to human be-
haviour and disease and to identify new therapeutic
approaches. To this end, we established SynSysNet
from a set of 1000 synapse specific proteins, their
structures and small-molecule interactions. For
two-thirds of these, 3D structures are provided
(from Protein Data Bank and homology modelling).
Drug-target interactions for 750 approved drugs and
50 000 compounds, as well as 5000 experimentally
validated protein–protein interactions, are included.
The resulting interaction network and user-selected
parts can be viewed interactively and exported in
XGMML. Approximately 200 involved pathways can
be explored regarding drug-target interactions.
Homology-modelled structures are downloadable
in Protein Data Bank format, and drugs are available
as MOL-files. Protein–protein interactions and drug-
target interactions can be viewed as networks;
corresponding PubMed IDs or sources are given.
INTRODUCTION
Synapses are specialized subcellular organelles connecting
nerve cells in the central nervous system or nerve cells and
muscle cells in the peripheral nervous system. Synapses act
by pre-synaptic release of synaptic transmitters and the
post-synaptic reception of the signal. Their outstanding
signiﬁcance for learning was explained by Donald Hebb
in 1949 with the phrase: ‘cells that wire together, ﬁre
together’ (1). This concept of synaptic plasticity means
that repetitive correlated ﬁring between neurons leads to
improved transmission between those neurons. To date,
important details of the underlying molecular mechanisms
involving the glutamate receptors and downstream
signalling proteins are known (2). More than 100 neuro-
logical diseases, such as autism or schizophrenia, are
associated with mutations of synaptic proteins (3), which
may represent novel therapeutic targets. Proteomic data
analysis may allow correlations between mutations in
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synaptic proteins and monogenic diseases to be found as
demonstrated by Bayes et al. (4). Using the international
classiﬁcation of diseases (ICD-10), they found that the
terms ‘psychiatry’ and ‘neurology’ (Chapters V and VI)
were predominant for synaptic proteins, which includes
neurodegenerative diseases like Parkinson’s or
Huntington’s, mental retardation and motor disorders,
such as dystonia or epilepsies.
A number of resources dedicated to the synapse were
developed and are listed in the Society for Neuroscience
Information Framework (http://neuinfo.org). More spe-
ciﬁcally, the SynDB (5), based on a synaptic ontology,
created a resource for 14 000 synaptic proteins (3000 in
humans). The Genes to Cognition database/SYNSYSdb
contains 5000 mammalian genes for synapse proteins and
associated information, including mutations, interactions
and so forth, aiming at warehousing data on the synaptic
proteome (6). Recently, the gene-centred database
SynaptomeDB compiled 1900 human synaptic genes (7)
that were linked to STRING (8), which provides informa-
tion about experimental and predicted protein–protein
interactions (PPIs).
Here, we present SynSysNet, which is based on an
expert-curated list of 1000 human genes that are speciﬁc
to the synapse. Information on the resulting proteins, their
3D structure, small molecules that bind to them and PPIs
was integrated. SynSys stands for ‘Synaptic Systems’
including synaptic gene function in different animal
models, and the SynSys consortium is dedicated to
systems biology of the synapse (http://synsys.eu; http://
synsysdb.genes2cognition.org) using various experimental
techniques to elucidate synaptic PPIs (9) and to develop
disease-oriented models. Therefore, the integration of a
conﬁdence score for experimental results such as the one
developed in HIPPIE (10) was important. To bridge the
gap between interaction proteomics and diseases, it will be
important to consider a therapy-oriented drug classiﬁca-
tion, which allows a mapping of drug-target relations onto
the PPI network of the synapse. To this end, the hierarch-
ical World Health Organization classiﬁcation assigning
Anatomical Therapeutic Chemical codes to drugs (ATC-
codes) (11) was implemented in SynSysNet. The complex-
ity and importance of the synaptic system, which involves
a large number of speciﬁc proteins and has been a target of
more drugs than any other human tissue, requires integra-
tive resources combining multiple data and analyses.
SynSysNet was developed to aid researchers to integrate
current structural and interaction data on synaptic
proteins with the aim of understanding the effect of
existing and potentially novel drug therapies.
MATERIALS AND METHODS
Manual curation of the list of synaptic genes was a
time-consuming step, requiring discussion between differ-
ent laboratories. Functional gene group analysis reveals a
role of synaptic heterotrimeric G proteins in cognitive
ability (12). The goal was the selection of the proteins
that occur speciﬁcally in the synapse. This excluded, for
example, the products of housekeeping genes, including
some prominent proteins of mitochondria, energy produc-
tion or carbohydrate metabolism, but generated a more
focused data set. UniProt mapping of gene names to
proteins (13) was used to identify the associated
proteins, and splice forms were obtained from Ensembl
(14). Drug-target relations were integrated from
SuperTarget (15) for all proteins from the list of the
SynSys consortium.
SynSysNet integrates PPIs with experimental evidence.
In contrast to other resources, predicted interactions are
not included in the database. Instead, there are two re-
sources, data from the SynSys consortium and articles
on experimental work, where only data with PubMed
IDs are displayed. Future releases of the database will
integrate new data from consortium partners. Automatic
text mining and Web-resources [see (16) for a list] were
used to generate a PPI network, which can be evaluated by
a normalized quality scoring scheme (10). This quality
score is computed using a function that takes into
account three components: the number of studies that
report a given PPI, the type of technique used for the
detection of the PPI and the number of species in which
orthologues of the human PPI partners have been experi-
mentally veriﬁed to interact. The evaluation of the tech-
niques was done in collaboration with experts in the
production of PPI data, and more direct methods were
scored more highly (e.g. X-ray crystallography). The
function was optimized to score reproducible interactions
most highly using leave-one-out re-sampling. In its SynSys
implementation, the original HIPPIE scores are rescaled
to integers between 0 and 10; values of 5 can be con-
sidered to indicate high-conﬁdence interactions. For
details about the HIPPIE score implementation see the
frequently asked questions on the website.
Server, database and system requirements
SynSysNet is a relational MySQL (http://www.mysql.com)
database. To handle the chemical information within the
database, the MyChem package (http://mychem.
sourceforge.net/) is used. MyChem relies for most of its
functions on the Open Babel toolbox (http://openbabel.
org). The website is built using PHP (http://www.php.net/
); web access is enabled through Apache HTTP Server
(http://httpd.apache.org/). We recommend a recent
version of Mozilla Firefox; alternate browsers Google
Chrome, Microsoft Internet Explorer and Apple Safari
were tested with some conﬁgurations. JavaScript must be
enabled, as Java is required to use all features of the site.
3D structures and homology models
To obtain 3D structures for the SynSys proteins and tem-
plate structures for modelling, a Basic Local Alignment
Search against the Protein Data Bank (PDB) (17) was per-
formed. Here, all non-redundant PDB sequences with a
sequence identity of 95% were selected. Modeller 9v10
was used for the homology modelling. The generation of
eachmodel is basedon thePDBstructure selected according
to identity, alignment length and E-value. The quality of
the 3D model was evaluated by the DOPE (18) score, a
DOPE-score plot for each model is provided.
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Visualization
The network of synaptic interactions, including drugs and
proteins, can be displayed interactively through CobWeb
(19), an open source Java applet for network exploration.
Pathway information is acquired from KEGG (20)
through Web service, and drug-target information is
shown on top in a pop-up layer. Protein structures can
be visually inspected using Jmol (21).
RESULTS AND DISCUSSION
Synaptic genes were manually curated to assure that
proteins were, based on PubMed data, correctly annotated
as synaptic. General ‘housekeeping’ enzymes (e.g. for
energy production or carbohydrate metabolism) were
excluded to obtain a focused data set. These criteria led
to a list of 1028 synaptic genes. The genes and associated
proteins (including synonyms, splice forms and so forth)
are available in the download section of the database.
Revised/extended versions of the list will be released in
upcoming versions of SynSysNet.
A total of 46 000 compounds were associated with the
synaptic proteins. The database comprises 69 000
compound-target relations. The corresponding PubMed
ID or resource can be retrieved by clicking on the edge
between targets in the network-view. For most of the
interactions, quantitative binding values are available.
A subset of 750 approved drugs (with ATC codes) ad-
dresses synaptic targets. Although 30% of all drugs
interact with synaptic targets, >60% of all ‘N-drugs’
(ATC code N, nervous system) occur in the network of
synaptic proteins. Other prominent ATC classes repre-
sented include C (cardiovascular, 40%), S (sensory
organs, 40%) and R (respiratory, 28%). Some of the
synaptic targets that cause this distribution of drug
frequencies in the network can be identiﬁed in Figure 1.
Well-represented drug classes in SynSysNet are
psycholeptics with 90 drugs (ATC code: N05), ophthalmo-
logicals with 72 drugs (S01), psychoanaleptics with 66
drugs (N06), cardiac therapeutics with 48 drugs (C01),
analgesics with 40 drugs (N02), drugs for obstructive
airway diseases with 32 agents (R03), anaesthetics with
29 drugs (N01), anti-epileptics with 27 drugs (N03) and
other nervous system drugs with 24 representatives (N07).
To date, 5000 PPIs, referenced by 8000 literature refer-
ences, can be explored; the quality score is used to draw
the thickness of the network edges in the interactive
network visualization. PPIs of the synapse generate a
complex dynamic network. Comprehension of this
network will be important for a deeper functional under-
standing of the synapses and their related diseases, the
so-called synaptopathies (3).
Compound PPIs are visualized in Figure 1. SynSysNet
provides interactive graphical Web access to these data,
allowing users to extend or reduce a network that can then
be exported in an XML format [XGMML, standard in
Cytoscape (22)]. Although, as it could be expected, the
drugs of the nervous system dominate this network,
other main classes of the ATC tree are represented.
Visual examination of the unbiased network graph
suggests that most of the approved drugs and their
targets occur in the outer shell of the graph. As proteins
with many interactions cluster in the centre of the graph,
this could have been caused by the fact that drugs target
preferentially synapse proteins with a small number of
interactions. However, we could not conﬁrm a signiﬁcant
difference in the degree distribution of protein interactions
of the proteins targeted by drugs versus those not targeted
(data not shown). This is in contrast to the observation
that cancer drugs target high degree proteins (23); this
could be taken as an indication that drug–protein
networks related to different tissues or diseases may
have different topological properties and require different
approaches.
An interesting feature evidenced by the drug–protein
graph is the existence of clusters of drugs. The reason is
that the majority of the drugs belonging to the same ATC
class share at least one target. Thereby those drugs accu-
mulate around this target and are located close to each
other. For instance, the N05 class contains psycholeptics,
which have an anti-psychotic, anxiolytic and sedative
effect, and generally target central nervous system
function. In Figure 1, the N05 class is divided into two
groups and each addresses a different 5-hydroxy-
tryptamine (serotonine) receptor. The lower group seems
to be more concentrated on one target the gamma-
aminobutyric acid (GABA) receptor, whereas the upper
group in the ﬁgure shares many interaction partners
with other ATC classes (N02, N04, N06). One neighbour
of the upper N05 group is N04, which acts against
Parkinson’s disease through an activation of the dopamin-
ergic system. It is plausible that these share targets because
it is known that psycholeptics inhibit the dopaminergic
system and often lead to undesirable side effects, such as
Parkinson’s-like symptoms. Accordingly, it can be
assumed that the lower N05 group will cause less
Parkinson’s-like adverse effects. Another example that
explains drug side effects on a molecular level is the
lower N03 cluster (anti-epileptics), which addresses a
primary target (sodium channel). This explains the thera-
peutic effect and the side effect hypertension because the
drug targeted sodium channel is also expressed in the
cardiac muscle.
As aforementioned, other ATC codes appear in this
synaptic network in addition to the N ATC group for
drugs, which have an effect in the nervous system. These
other drugs belong to the S (sensory organs), R (respira-
tory system) and C (cardiovascular system) ATC groups.
This presence can be explained by their interacting targets,
which are not only expressed in the central nervous system
but also in other tissues. For example, the S01 and R03
groups share the M1- and M2-type muscarinic acetylcho-
line receptor targets. These receptors have physiological
functions in different tissues; therefore, they occur in the
central nervous system as well as in lung and sensory
organs. The tissue distribution of these receptors is im-
portant for the S01 and R03 groups, which contain oph-
thalmologicals (S01) and drugs for obstructive airway
diseases (R03). Therefore, they are only used topically
and do not affect the muscarinic acetylcholine receptor
in the brain.
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Another example is the ATC group C, which contains
drugs against cardiovascular diseases. Some of those drugs
inhibit the Na(+)/K(+)-adenosine triphosphatase, which
plays a major role in the physiological function of every
cell and is highly important for neuronal function. As this
transporter is broadly expressed, these drugs have a
narrow therapeutic window. For example, one of these
C-group drugs, digitoxin, causes abnormal colour vision
as a side effect, possibly by affecting synapses in the
central nervous system.
SynSysNet was developed as a user-friendly platform,
and Figure 2 shows the use of some features of the website
exempliﬁed by exploration of the Parkinson’s drug–PPI
network. The navigation bar in the upper area offers
downloads, answers to frequently asked questions, links
and so forth.
There are three ways to explore a drug–PPI network:
(i) The ‘Proteins’ button, illustrated in Step 1, enables
the user to type in a protein name or common IDs
(e.g. the dopamine D2 receptor, which is a major
target of the medication for Parkinson’s disease) or
any ID. It is also possible to search by the function
of a protein. Clicking on ‘Find’ leads to a list of
detailed information on the protein, including local-
ization, 3D structures. Clicking on the button
‘Network view’ on the top of the page leads to
the compound–PPI network, as shown in Step 3.
(ii) The user is able to search for compounds as well as
ATC codes (e.g. L-dopa or N04BA01) by clicking
on the ‘Compounds’ button. Information about the
drug L-dopa is shown in Step 2. It is possible to get
a ‘network view’ or to get information on ‘interact-
ing targets’ or ‘pathways’ by clicking on these links.
The occurrence of synaptic proteins in 200
KEGG-pathways and in 30 synapse speciﬁc
pathways can be explored, and the binding com-
pounds can be displayed (for details see Figure 3).
(iii) ‘Interactions’ are illustrated in Step 3, where the
user is able to directly search for a speciﬁc
network by a number of drugs/targets or predeﬁned
disease networks. The example shows the network
of Parkinson’s disease. The dopamine receptor is
shown with 30 neighbours (default: 15 targets and
15 drugs); all neighbours can be listed by clicking on
‘show neighbours’, and a distinct number can be
added by clicking ‘load x neighbours’ on the right
side of the network. Detailed information on
speciﬁc targets (e.g. a-synuclein) can be viewed in
a separate tab. The dopamine receptors are sur-
rounded by a number of drugs in the right upper
corner of the network. Most of them act on both
D(1) and D(2) receptors. The relation to other
mechanisms of action, like inhibition of the glutam-
ate- (NMDA), monoamine-oxidase- (MAO-A/B)
and muscarinergic receptors, can be explored in
this graph. Corresponding drugs (amantadine,
rasagiline and biperiden) and other compounds are
displayed. a-Synuclein is a soluble protein that regu-
lates dopamine secretion and generates membrane
channels. Mutations are responsible for different
versions of Parkinson’s disease and so-called
Lewy-bodies, which are synuclein-inclusions.
a-Synuclein automatically appears in the SynSys
drug–PPI network of Parkinson’s disease.
a-Synuclein is the promising target of a novel vac-
cination therapy against Parkinson’s disease that
has reached the phase of clinical trials (24). Other
promising targets like dopamine transporter or
tyrosine hydroxylase and associated compounds
can be identiﬁed in the SynSys drug–PPI network.
Some network exploration options are illustrated in
Figure 3, with the examples of a-Synuclein and the
dopamine receptor. In Step 4, clicking on the edges of
the interaction graph gives PubMed IDs (clickable) or
resource and experimental conﬁdence scores (weight).
For the target under examination, more neighbours can
be loaded into the visualization (individually from a list or
a deﬁned number). The ‘view detailed info’ option leads to
more information, including KEGG pathways, which
Figure 1. Drug–PPI network. This compound–PPI network shows the
interactions between 1160 compounds and 894 proteins. To create the
network, compounds and connected proteins from SynSysNet were
chosen. The proteins, the compounds and the interactions were
loaded into Cytoscape (22); a graph layout minimizing the total path
length (spring embedded, edge-weighted layout) was used. A total of
6116 interactions (edges), composed of 4318 PPIs and 1798 compound–
protein interactions, are shown. Compounds are represented by ruby
circles and proteins by green circles, and the edges between them are
blue. Some compounds have the same target; therefore, they are clus-
tered into groups. The clusters were analysed, and they were found to
contain many compounds belonging to the same ATC code (high-
lighted). Most of the clusters comprise drugs of the nervous system
(N) ATC group. The N01 cluster, which represents anaesthetics, is
highlighted white, N02 (analgesics) light-blue, N03 (anti-epileptics)
orange, N04 (anti-Parkinson’s drugs) dark-blue, N05 (psycholeptics)
green and N06 (psychoanaleptics) pink. Besides the nervous system
ATC codes, drugs from other ATC groups occur, sensory organs (S),
respiratory system (R) and cardiovascular system (C). There are S01
codes (ophthalmologicals) highlighted in red, S01 and S03 (ophthalmo-
logical and otological preparations) combined in red violet, S01 and
R03 (drugs for obstructive airway diseases) combined in purple and the
cardiovascular system (C) in yellow.
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complement the network view because here, the targets are
grouped according to functional or pathological units.
Recently, it was shown that PPI networks could be
exploited to ﬁnd novel targets and to judge their
druggability (25,26). The mapping of drug-target relations
onto the network of synaptic PPIs will enable new ques-
tions to be asked, for instance: what is the reason for an
adverse effect of a drug in the (central) nervous system?
The value of high quality PPIs for such systems-level
understanding of disease and therapy cannot be
overestimated (27). Data like localization, dynamics and
quantitative aspects like stoichiometry and binding
afﬁnities will extend existing PPIs (28). The yet prelimin-
ary data on pre-/post-synaptic and vesicular localization
will be scrutinized during the project, data on PPIs will
grow, new disease models will be developed and known
3D structures of synapse proteins will be used to generate
larger protein complexes according to experimental data.
Synaptic proteins and synaptic protein interactions are
crucially contributing to synaptic function and plasticity
in health and disease. Given the socio-economic impact of
brain disease and the substantial role of synaptopathies in
these, we expect that speciﬁcally targeting certain synaptic
proteins, or synaptic protein interactions, will become
highly important in the years to come.
The newly established compound–PPI network will aid
the understanding of complex interactions between trans-
mitters, drugs and synaptic proteins, which could explain
various pathological conditions as well as the adverse
effects of drugs. SynSysNet will gain more predictive
value as more data on PPIs will become known.
Notably, large-scale efforts to map the synaptic
interactome are ongoing and will be used to continuously
update SynSysNet.
AVAILABILITY
SynSysNet is available through the website without regis-
tration: http://bioinformatics.charite.de/synsys. It can be
used under the terms of the Creative Commons
Attribution-Noncommercial-Share Alike 3.0 License.
Figure 2. A SynSysNet example query. Step 1 shows the search for a protein, in this example the D2 dopamine receptor. By clicking on the ‘Find’
button, the result list will open on the next page with detailed information like synonyms, IDs, function, gene information, pathways and PDB
structures/3D models. The button ‘Network view’ leads to an interactive network visualized by CobWeb, which shows the interacting proteins and
drugs. Step 2 illustrates the search for a compound either by name, for example, L-dopa, or by the ATC code, for example, N04BA01. The results
will be presented on the next page, again with detailed information about the compound, particularly the interacting targets, in this case D(1A) and
D(2) dopamine receptor. Finally, in Step 3, an interactive network from the disease, for example, ‘Parkinson’s disease’, is shown. For every protein
and compound, detailed information is provided (see the button ‘‘view detailed info’’), including complete ‘neighbourhood’ (drugs and targets).
D838 Nucleic Acids Research, 2013, Vol. 41, Database issue
ACKNOWLEDGEMENTS
The authors thank the colleagues of the SynSys consor-
tium for the contribution of experimental data on PPIs.
FUNDING
European Union Seventh Framework Programme
SYNSYS (Synaptic Systems: dissecting brain function in
health and disease), HEALTH-2009-2.1.2-1, under grant
agreement no [242167]; Deutsche Forschungsgemeinschaft
[GRK1772, GRK1360]. Funding for open access charge:
European Union, FP7, SynSys.
Conﬂict of interest statement. None declared.
REFERENCES
1. Whitcomb,D.J., Regan,P. and Cho,K. (2011) The synapse and
brain function. Semin. Cell Dev. Biol., 22, 488–491.
2. Yuzaki,M. (2009) New (but old) molecules regulating synapse
integrity and plasticity: Cbln1 and the delta2 glutamate receptor.
Neuroscience, 162, 633–643.
3. Grant,S.G. (2012) Synaptopathies: diseases of the synaptome.
Curr. Opin. Neurobiol., 22, 522–529.
4. Bayes,A., van de Lagemaat,L.N., Collins,M.O., Croning,M.D.,
Whittle,I.R., Choudhary,J.S. and Grant,S.G. (2011)
Characterization of the proteome, diseases and evolution
of the human postsynaptic density. Nat. Neurosci., 14, 19–21.
5. Zhang,W., Zhang,Y., Zheng,H., Zhang,C., Xiong,W.,
Olyarchuk,J.G., Walker,M., Xu,W., Zhao,M., Zhao,S. et al.
(2007) SynDB: a Synapse protein DataBase based on synapse
ontology. Nucleic Acids Res., 35, D737–D741.
6. Croning,M.D., Marshall,M.C., McLaren,P., Armstrong,J.D. and
Grant,S.G. (2009) G2Cdb: the genes to cognition database.
Nucleic Acids Res., 37, D846–D851.
7. Pirooznia,M., Wang,T., Avramopoulos,D., Valle,D., Thomas,G.,
Huganir,R.L., Goes,F.S., Potash,J.B. and Zandi,P.P. (2012)
SynaptomeDB: an ontology-based knowledgebase for synaptic
genes. Bioinformatics, 28, 897–899.
8. von Mering,C., Jensen,L.J., Kuhn,M., Chaffron,S., Doerks,T.,
Kruger,B., Snel,B. and Bork,P. (2007) STRING 7—recent
developments in the integration and prediction of protein
interactions. Nucleic Acids Res., 35, D358–D362.
Figure 3. Network exploration options. Step 4 shows the example of a subnetwork for a-synuclein. On the right side, references with links to
PubMed are displayed. The circles correspond to self-interactions. The weight of 8.0 and the circle in the graph correspond to the experimental
conﬁdence score of synuclein–synuclein interactions (see ‘Materials and Methods’ section). In Step 5, additional interactors of a-synuclein were
loaded. The network can be exported in its current form in XGMML format through the button in the upper right corner. Detailed information on
the compounds can be displayed in a new tab. At the bottom of the details page, pathways for different diseases are listed and can be viewed as
shown here for Parkinson’s disease (enriched KEGG pathway). Yellow boxes indicate KEGG targets with drug info in SynSysNet. Mouse-over
results in a tool-tip (pop-up) that contains detailed drug-target information.
Nucleic Acids Research, 2013, Vol. 41, Database issue D839
9. Li,K.W., Klemmer,P. and Smit,A.B. (2010) Interaction
proteomics of synapse protein complexes. Anal. Bioanal. Chem.,
397, 3195–3202.
10. Schaefer,M.H., Fontaine,J.F., Vinayagam,A., Porras,P.,
Wanker,E.E. and Andrade-Navarro,M.A. (2012) HIPPIE:
integrating protein interaction networks with experiment based
quality scores. PLoS One, 7, e31826.
11. WHO Expert Committee. (2009) The selection and use of
essential medicines. World Health Organ. Tech. Rep. Ser.,
1–242.
12. Ruano,D., Abecasis,G.R., Glaser,B., Lips,E.S., Cornelisse,N.L.,
de Jong,A.P.H., Evans,D.M., Davey,S.G., Timpson,N.J.,
Smit,A.B. et al. (2010) Interaction proteomics of synapse protein
complexes. Am. J. Hum. Genet., 86, 113–125.
13. UniProt Consortium. (2012) Reorganizing the protein space at
the Universal Protein Resource (UniProt). Nucleic Acids Res., 40,
D71–D75.
14. Flicek,P., Amode,M.R., Barrell,D., Beal,K., Brent,S., Carvalho-
Silva,D., Clapham,P., Coates,G., Fairley,S., Fitzgerald,S. et al.
(2012) Ensembl 2012. Nucleic Acids Res., 40, D84–D90.
15. Hecker,N., Ahmed,J., von Eichborn,J., Dunkel,M., Macha,K.,
Eckert,A., Gilson,M.K., Bourne,P.E. and Preissner,R. (2012)
SuperTarget goes quantitative: update on drug-target interactions.
Nucleic Acids Res., 40, D1113–D1117.
16. Kamburov,A., Pentchev,K., Galicka,H., Wierling,C., Lehrach,H.
and Herwig,R. (2011) ConsensusPathDB: toward a more
complete picture of cell biology. Nucleic Acids Res., 39,
D712–D717.
17. Rose,P.W., Beran,B., Bi,C., Bluhm,W.F., Dimitropoulos,D.,
Goodsell,D.S., Prlic,A., Quesada,M., Quinn,G.B., Westbrook,J.D.
et al. (2011) The RCSB Protein Data Bank: redesigned web site
and web services. Nucleic Acids Res., 39, D392–D401.
18. Mathur,A., Shankaracharya. and Vidyarthi,A.S. (2012) SWIFT
MODELLER v2.0: a platform-independent GUI for homology
modeling. J. Mol. Model., 18, 3021–3023.
19. von Eichborn,J., Bourne,P.E. and Preissner,R. (2011)
Cobweb: a Java applet for network exploration and visualisation.
Bioinformatics, 27, 1725–1726.
20. Kanehisa,M., Goto,S., Sato,Y., Furumichi,M. and Tanabe,M.
(2012) KEGG for integration and interpretation of large-scale
molecular data sets. Nucleic Acids Res., 40, D109–D114.
21. Hanson,R.M. (2010) Jmol - a paradigm shift in crystallographic
visualization. J. Appl. Cryst., 43, 1250–1260.
22. Smoot,M.E., Ono,K., Ruscheinski,J., Wang,P.L. and Ideker,T.
(2011) Cytoscape 2.8: new features for data integration and
network visualization. Bioinformatics, 27, 431–432.
23. Hase,T., Tanaka,H., Suzuki,Y., Nakagawa,S. and Kitano,H.
(2009) Structure of protein interaction networks and their
implications on drug design. PLoS Comput. Biol., 5, e1000550.
24. Schneeberger,A., Mandler,M., Mattner,F. and Schmidt,W. (2012)
Vaccination for Parkinson’s disease. Parkinsonism Relat. Disord.,
18(Suppl. 1), S11–S13.
25. Zhang,M., Su,S., Bhatnagar,R.K., Hassett,D.J. and Lu,L.J. (2012)
Prediction and analysis of the protein interactome in
Pseudomonas aeruginosa to enable network-based drug target
selection. PLoS One, 7, e41202.
26. De Las Rivas,J. and Prieto,C. (2012) Protein interactions:
mapping interactome networks to support drug target discovery
and selection. Methods Mol. Biol., 910, 279–296.
27. Stelzl,U. and Wanker,E.E. (2006) The value of high quality
protein-protein interaction networks for systems biology. Curr.
Opin. Chem. Biol., 10, 551–558.
28. Sorokina,O., Sorokin,A. and Armstrong,J.D. (2011) Towards a
quantitative model of the post-synaptic proteome. Mol. Biosys., 7,
2813–2823.
D840 Nucleic Acids Research, 2013, Vol. 41, Database issue
